The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: MIM-D3

Mimetogen Pharmaceuticals Sews Up Financing Through Phase II POC

Mimetogen Pharmaceuticals, a pharma company developing peptidomimetics based on technology from McGill University and the Lady Davis Institute for Medical Research in Montréal, closed a new financing from iNovia Capital and VIMAC Ventures LLC

The amount of the financing was not disclosed, but it is budgeted to take Mimetogen’s lead product, MIM-D3 for keratoconjunctivitis sicca (dry eye syndrome), through both Phase I safety and tolerability and Phase II proof of concept studies in humans.

Mimetogen has other products in the pipeline for ophthalmic indications, and plans to focus on partnering for development of its leads for other indications (e.g., neurodegenerative disease and pain).

H/T @chrisarsenault @CVCACanada

Bookmark and Share


Get every new post delivered to your Inbox.

Join 128 other followers